Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 53, 2023 - Issue 5
59
Views
0
CrossRef citations to date
0
Altmetric
Xenobiotic transporters

Two curcumin analogs inhibited the function and protein expression of breast cancer resistance protein: in vitro and in vivo studies

, , , , , & show all
Pages 454-464 | Received 01 Aug 2023, Accepted 15 Sep 2023, Published online: 25 Sep 2023
 

Abstract

1. Two curcumin analogs, (1E,6E)-1,7-bis(3,5-diethyl-4-hydroxyphenyl)hepta-1,6-diene-3,5- dione (N17) and its prodrug ((1E,6E)-3,5-dioxohepta-1,6-diene-1,7-diyl)bis(2,6-diethyl-4,1- phenylene)bis(3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate) (N17′), were evaluated as breast cancer resistance protein (BCRP) inhibitors.

2. MDCKII-BCRP and MDCKII-WT were used to evaluate the modulation effects of N17 and N17′ on BCRP and to explore the relevant mechanism. Sprague-Dawley rats were orally administered rosuvastatin (ROS), a probe substrate of BCRP, without and with N17′ (100 mg/kg) to investigate the effect of N17′ on ROS pharmacokinetics.

3. In cell studies, N17 and N17′ were substrates of BCRP, and they decreased the activity and protein expression of BCRP. In rat study, N17′ increased the systemic exposure of ROS by 218% (p = 0.058).

4. N17 and N17′ are potential BCRP inhibitors and will be promising candidates for overcoming the BCRP-mediated multidrug resistance.

Disclosure statement

The authors have declared no conflict of interest.

Additional information

Funding

This work was supported by the Ministry of Science and Technology, Taiwan, ROC under Grant [MOST 108-2320-B-039-041-MY3, MOST 111-2320-B-039-048]; China Medical University, Taiwan, ROC under Grant [CMU110-S-06]; China Medical University Hospital, Taiwan, ROC under Grant [DMR-108-146]; and ‘Chinese Medicine Research Center, China Medical University’ from the Featured Areas Research Centre Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan under Grant [CMRC-CHM-3-2].

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.